Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...

Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2024 Financial and Operational Review Protalix Biotherapeutics, Inc.

A new Ottawa biotech startup is seeking to raise $4 million to produce groundbreaking treatments aimed at curing one of the ...

TD Cowen analyst Brendan Smith maintained a Hold rating on Codexis (CDXS – Research Report) today and set a price target of $3.00. The ...

Biopharma & medical devices cos view advanced infrastructure to propel manufacturing & new drug development: Nandita Vijayasimha, Bengaluru Saturday, November 16, 2024, 08:00 Hrs ...

The global animal model market is expected to grow from USD 1,943.3 million in 2024 to USD 3,476.8 million by 2034, at a CAGR ...

Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

A new technology that delivers two halves of a gene separately could enable gene therapy treatments of muscular dystrophies.